GLS4 莫非賽定 Morphothiadin

具體成交價以合同協議為準

公司名稱 MedChemExpress LLC
品牌 MedChemExpress (MCE)
型號 GLS4
產地
廠商性質 生產廠家
更新時間 2019/6/27 8:50:13
訪問次數 722

產品標簽

GLS4 morphothiadin

在線交流發送詢價查看電話同類產品

聯系我們時請說明是化工儀器網上看到的信息，謝謝!

索取相關資料

公司介紹 主營產品

MedChemExpress (MCE) 專注于為科學家提供高品質的生物活性小分子化合物，化合物庫及各類試劑盒，總部位于美國新澤西。
•   MedChemExpress (MCE) 產品作用于 20 多個熱門信號通路及研究領域的300多個細分靶點，擁有 10000 特異性抑制劑、激動劑，以及 50 活性化合物篩選庫；
•   我們堅持對所有產品進行嚴格質檢，確保產品的高品質和高純度；
•   MedChemExpress (MCE) 產品已被數萬名科學家信賴，并被大量top文獻和*引用；
•   我們擁有專業的技術團隊追蹤前沿科研進展，不斷豐富各個靶點的特異性產品，堅持做 “您身邊的抑制劑大師”；
•   MedChemExpress (MCE) 與眾多藥企和科研機構保持深度合作；
•   大量產品有中國庫存，工作日 16:00 前訂單確保當日發貨，次日送達。
MCE 中國站：www.MedChemExpress.cn

Hotline: 400-820-3792
Tel: 021-58955995
Email: sales@MedChemExpress.cn
Tech Support: 021-58950656

MedChemExpress - Inhibitors Agonists

MedChemExpress - Screening Libraries

MedChemExpress - Top Publications Citing Use of MCE

展開

抑制劑，調節劑，API，天然產物，各種類型化合物庫

詳細信息 在線詢價

供貨周期	現貨	規格	10 mM * 1 mL；1 mg；5 mg；10 mg；25 mg；50 mg
貨號	HY-108917	應用領域	生物產業

Morphothiadin

產品活性：Morphothiadin 是野生型和阿德福韋耐藥 HBV 復制的有效抑制劑，其 IC₅₀ 值為 12 nM。

研究領域：Anti-infection

作用靶點：HBV

In Vitro: Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir-resistant HBV with an IC₅₀ of 12 nM. Morphothiadin (GLS4) shows no toxicity up to 25 μM. The cytotoxic dose whereby 50% of cells die (CC₅₀) for primary hepatocytes is 115 μM for Morphothiadin (P<0.001). The CC₉₀ is 190 μM for Morphothiadin (P<0.01) in HepAD38 cells. Morphothiadin strongly inhibits virus accumulation in the supernatant of HepAD38 cells at 25 nM to 100 nM (P<0.02). Results show a concentration-dependent decrease of core protein in cells treated with Morphothiadin.

In Vivo: The area under the concentration-time curve from 0 to 24 h (AUC_0-24) of Morphothiadin (GLS4) is 556 h?ng/mL. After intravenous administration of 10 mg/kg Morphothiadin, the total plasma clearance and apparent volume distribution are 4.2 liters/h/kg and 7.38 liters/kg, respectively. The bioavailability of Morphothiadin is 25.5%. It is found that virus titers have increased 83.5-fold in mice treated with 3.75 mg/kg per day of Morphothiadin, 28.3-fold among mice treated with 7.5 mg/kg per day, but only 3- to 6-fold among mice treated with the higher doses of Morphothiadin. There is generally an inverse relationship between Morphothiadin dose and virus titer, with the greatest rebound seen in mice treated with 3.75 mg/kg per day of Morphothiadin (540-fold) and the smallest rebound in mice treated with 60 mg/kg per day (23-fold) (P<0.001). The Morphothiadin doses of >7.5 mg/kg per day significantly suppresses the virus replication cycle throughout the treatment period, while Morphothiadin doses of >15 mg/kg per day suppresses virus for up to 2 weeks after the end of treatment.